Cargando…

Analysis of Risk Factors for Adverse Cardiovascular Events in Elderly Patients with Acute Myocardial Infarction and Non-Alcoholic Fatty Liver Disease (NAFLD)

BACKGROUND: The present research aimed to explore the risk factors for adverse cardiovascular events in elderly patients with acute myocardial infarction (AMI) combined with NAFLD. MATERIAL/METHODS: We included 325 AMI patients hospitalized in the Department of Cardiology. AMI patients underwent eme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xia, Wei, Yang, Ning, Li, Yuming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2020
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288831/ https://www.ncbi.nlm.nih.gov/pubmed/32475980 http://dx.doi.org/10.12659/MSM.922913

Ejemplares similares

Key Genes Associated with Non-Alcoholic Fatty Liver Disease and Acute Myocardial Infarction
por: Dai, Weiran, et al.
Publicado: (2020)

Deterioration of Heart Rate Recovery Index in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Ozveren, Olcay, et al.
Publicado: (2014)

Visfatin associated with major adverse cardiovascular events in patients with acute myocardial infarction
por: Zheng, Meifan, et al.
Publicado: (2020)

Non-alcoholic fatty liver disease (NAFLD), metabolic syndrome and cardiovascular events in atrial fibrillation. A prospective multicenter cohort study
por: Pastori, Daniele, et al.
Publicado: (2021)

Recommendations for the management of non-alcoholic fatty liver disease (NAFLD)
por: Tomasiewicz, Krzysztof, et al.
Publicado: (2018)

Irisin Is Related to Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Kosmalski, Marcin, et al.
Publicado: (2022)

Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
por: Rong, Li, et al.
Publicado: (2023)

In Vitro and in Vivo Models of Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Kanuri, Giridhar, et al.
Publicado: (2013)

Nutritional Intake and the Risk for Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Schattenberg, Jörn M., et al.
Publicado: (2019)

Physiopathology of Lifestyle Interventions in Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Carneros, David, et al.
Publicado: (2020)

Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD)
por: Parameswaran, Madhangi, et al.
Publicado: (2021)

What’s New in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Kosmalski, Marcin, et al.
Publicado: (2023)

Cardiovascular disease in patients with non-alcoholic fatty liver disease
por: Kantartzis, Konstantinos, et al.
Publicado: (2012)

A poor perspective of self weight significantly increases adverse outcomes in non-alcoholic fatty liver disease (NAFLD)
por: Fu, Clarissa Elysia, et al.
Publicado: (2022)

Fatty Liver Index is a valid predictor of non-alcoholic fatty liver disease (NAFLD) in pregnancy
por: Koralegedara, Iresha Sandamali, et al.
Publicado: (2022)

Non-alcoholic fatty liver disease (NAFLD) and the cardiovascular disease (CVD) risk categories in primary care: is there an association?
por: Miptah, Hayatul Najaa, et al.
Publicado: (2020)

The Importance of the Fatty Acid Transporter L-Carnitine in Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Savic, Dragana, et al.
Publicado: (2020)

Prevalence and association of medication nonadherence with major adverse cardiovascular events in patients with myocardial infarction
por: Hou, Yunfeng, et al.
Publicado: (2019)

Plasmatic higher levels of homocysteine in Non-alcoholic fatty liver disease (NAFLD)
por: de Carvalho, Sylene Coutinho Rampche, et al.
Publicado: (2013)

Non-alcoholic fatty liver disease (NAFLD): a tale of fat and sugar?
por: Longato, Lisa
Publicado: (2013)

Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Saeed, Ali, et al.
Publicado: (2017)

Cohort profile: the Trivandrum non-alcoholic fatty liver disease (NAFLD) cohort
por: Chalmers, Jane, et al.
Publicado: (2019)

Non-alcoholic fatty liver disease (NAFLD) and risk of hospitalization for Covid-19.
por: Bramante, Carolyn T., et al.
Publicado: (2020)

The Role of Resolvins, Protectins and Marensins in Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Maciejewska-Markiewicz, Dominika, et al.
Publicado: (2021)

Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences
por: Tripodi, Armando, et al.
Publicado: (2022)

Terpenoids: Natural Compounds for Non-Alcoholic Fatty Liver Disease (NAFLD) Therapy
por: Yao, Pengyu, et al.
Publicado: (2022)

Emerging role of nanotechnology in treatment of non-alcoholic fatty liver disease (NAFLD)
por: Moghtadaie, Atie, et al.
Publicado: (2023)

Cardiovascular events and death after myocardial infarction or ischemic stroke in an older Medicare population
por: Li, Suying, et al.
Publicado: (2019)

The impact of platelet function or C-reactive protein, on cardiovascular events after an acute myocardial infarction
por: Modica, Angelo, et al.
Publicado: (2009)

Echocardiographic Parameters Predict Short- and Long-Term Adverse Cardiovascular Events in Patients with Acute Myocardial Infarction
por: Han, Meng-Meng, et al.
Publicado: (2021)

Serum irisin correlates to the severity of acute myocardial infarction and predicts the postoperative major adverse cardiovascular events
por: Chai, Qiaoying, et al.
Publicado: (2023)

Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis
por: Wu, Shunquan, et al.
Publicado: (2016)

Trends in conventional cardiovascular risk factors and myocardial infarction subtypes among young Chinese men with a first acute myocardial infarction
por: Zhang, Min, et al.
Publicado: (2021)

The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease
por: Cichoż-Lach, Halina, et al.
Publicado: (2012)

The Role of Invasive Therapies in Elderly Patients with Acute Myocardial Infarction
por: Nicolau, José C., et al.
Publicado: (2009)

Managed Care after Acute Myocardial Infarction (KOS-zawał) reduces major adverse cardiovascular events by 45% in 3-month follow-up – single-center results of Poland’s National Health Fund program of comprehensive post-myocardial infarction care
por: Wita, Krystian, et al.
Publicado: (2019)

Association of triglyceride levels with adverse cardiovascular events in patients with ST-segment elevation myocardial infarction
por: Yildiz, Mehmet, et al.
Publicado: (2023)

4448 Mental Stress Induced Myocardial Ischemia as a Marker for Adverse Cardiovascular Events After MI
por: Almuwaqqat, Zakaria, et al.
Publicado: (2020)

The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD)
por: Liu, Qing, et al.
Publicado: (2010)

Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence
por: Cicero, Arrigo F. G., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ma8e6c9j88dl5mgpa739rmsiel